Clinical correlation of brachial artery flow-mediated dilation in patients with systemic sclerosis

REFERENCES

• Asano Y. Future treatments in systemic sclerosis. J Dermatol. 2010;37:54–70.
   PubMed Web of Science ®Google Scholar
• Asano Y, Stawski L, Hant F, Highland K, Silver R, Szalai G, et al. Endothelial Flil deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol. 2010;176: 1983–98.
   PubMed Web of Science ®Google Scholar
• Koch AE, Distler 0. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther. 2007;9\(Suppl 2):53.
   Google Scholar
• Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, Abraham DJ. Shared expression of phenotypic markers in sys-temic sclerosis indicates a convergence of pericytes and fibro-blasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther. 2005;7:R1113–23.
   PubMed Web of Science ®Google Scholar
• Horn A, Distler JH. Vascular alterations upon activation of TGFbeta signaling in fibroblasts-implications for systemic sclerosis. Arthritis Res Ther. 2010;12:125.
   PubMed Web of Science ®Google Scholar
• Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endo-thelial dysfunction in children and adults at risk of atheroscle-rosis. Lancet. 1992;340:1111–5.
   PubMed Web of Science ®Google Scholar
• Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circula-tion. 1995;91:1314–9.
   PubMed Web of Science ®Google Scholar
• Peng X, Haldar S, Deshpande S, Irani K, Kass DA. Wall stiffness suppresses Akt/eNOS and cytoprotection in pulse-perfused endothelium. Hypertension. 2003;41:378–81.
   Google Scholar
• Li M, Chiou KR, Bugayenko A, Irani K, Kass DA. Reduced wall compliance suppresses Akt-dependent apoptosis protection stimulated by pulse perfusion. Circ Res. 2005;97:587–95.
   Google Scholar
• Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension. 2011;57:363–9.
   Google Scholar
• Lekakis J, Papamichael C, Mavrikakis M, Voutsas A, Stamate-lopoulos S. Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis. Am J Cardiol. 1998;82(1555-7):A8.
   Google Scholar
• Lekakis J, Mavrikakis M, Papamichael C, Papazoglou S, Economou 0, Scotiniotis I, et al. Short-term estrogen adminis-tration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. Am Heart J. 1998;136:905–12.
   Google Scholar
• Szucs G, Timár 0, Szekanecz Z, Der H, Kerekes G, Szamosi S, et al. Endothelial dysfunction precedes atherosclerosis in sys-temic sclerosis-relevance for prevention of vascular complica-tions. Rheumatology (Oxford). 2007;46:759–62.
   Google Scholar
• Bartoli F, Blagojevic J, Bacci M, Fiori G, Tempestini A, Conforti ML, et al. Flow-mediated vasodilation and carotid intima-media thickness in systemic sclerosis. Ann N Y Acad Sci. 2007;1108: 283–90.
   PubMedGoogle Scholar
• Rollando D, Bezante GP, Sulli A, Balbi M, Panico N, Pizzorni C, et al. Brachial artery endothelial-dependent flow-mediated dila-tion identifies early-stage endothelial dysfunction in systemic sclerosis and correlates with nailfold microvascular impairment. J Rheumatol. 2010;37:1168–73.
   PubMed Web of Science ®Google Scholar
• Rossi P, Granel B, Marziale D, Le Mée F, Frances Y. Endothelial function and hemodynamics in systemic sclerosis. Clin Physiol Funct Imaging. 2010;30:453–9.
   PubMed Web of Science ®Google Scholar
• Cypiene A, Laucevicius A, Venalis A, Dadoniene J, Ryliskyte L, Petrulioniene Z, et al. The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function. Clin Rheu-matol. 2008;27:1517–22.
   PubMed Web of Science ®Google Scholar
• Giannattasio C, Pozzi M, Gardinali M, Gradinali M, Montemerlo E, Citterio F, et al. Effects of prostaglandin El alpha cyclodextrin [corrected] treatment on endothelial dysfunction in patients with systemic sclerosis. J Hypertens. 2007;25:793–7.
   PubMedGoogle Scholar
• Andersen GN, Mincheva-Nilsson L, Kazzam E, Nyberg G, Klintland N, Petersson AS, et al. Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide pro-duction. Arthritis Rheum. 2002;46:1324–32.
   PubMed Web of Science ®Google Scholar
• Roustit M, Simmons GH, Baguet JP, Carpentier P, Cracowski JL. Discrepancy between simultaneous digital skin microvascular and brachial artery macrovascular post-occlusive hyperemia in systemic sclerosis. J Rheumatol. 2008;35:1576–83.
   Google Scholar
• LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classifica-tion, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.
   PubMed Web of Science ®Google Scholar
• Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol. 1993;20:1892–6.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum. 2007;56:1985–93.
   PubMedGoogle Scholar
• Cotton SA, Herrick AL, Jayson MI, Freemont AJ. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol. 1999;189:273–8.
   PubMed Web of Science ®Google Scholar
• Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethyl-arginine. Rheumatology (Oxford). 2006;45:676–84.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Nagai Y, Tamura A, Ishikawa 0. Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol. 2006;155:1159–64.
   Google Scholar
• Stafford L, Englert H, Gover J, Bertouch J. Distribution of macrovascular disease in scleroderma. Ann Rheum Dis. 1998; 57:476–9.
   PubMed Web of Science ®Google Scholar
• Youssef P, Englert H, Bertouch J. Large vessel occlusive disease associated with CREST syndrome and scleroderma. Ann Rheum Dis. 1993;52:464–6.
   Google Scholar
• Maurer B, Reich N, Juengel A, Kriegsmann J, Gay RE, Schett G, et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis. 2012;71:1382–7.
   PubMed Web of Science ®Google Scholar
• Furuya Y, Okazaki Y, Kaji K, Sato S, Takehara K, Kuwana M. Mobilization of endothelial progenitor cells by intravenous cyclophosphamide in patients with systemic sclerosis. Rheuma-tology (Oxford). 2010;49:2375–80.
   PubMed Web of Science ®Google Scholar
• Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA, Hazned-aroglu IC, et al. Effects of oral cyclophosphamide and prednis-olone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum. 2003;48:2256–61.
   Google Scholar
• Michalska-Jakubus M, Kowal-Bielecka 0, Chodorowska G, Bielecki M, Krasowska D. Angiopoietins-1 and -2 are differen-tially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatology (Oxford). 2011; 50:746–55.
   Google Scholar